Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts 313
Year : 2014  |  Volume : 5  |  Issue : 2  |  Page : 166-173

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin

Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India

Correspondence Address:
Santosh Kumar Singh
Department of Pharmacology, Armed Forces Medical College, Sholapur Road, Pune - 411 040, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0975-9727.135761

Rights and Permissions

The incidence of type 2 diabetes mellitus (T2DM) is increasing worldwide. The existing therapeutic classes of antidiabetic drugs are not adequately effective in maintaining long-term glycemic control in most patients, even when used in combination. Many marketed compounds do not address relevant aspects of the disease. In addition, side effects for established therapies such as hypoglycemia and weight gain have to be controlled. One emerging novel therapeutic class of antidiabetic drugs is sodium glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 accounts for 90% of the glucose reabsorption in the kidney. The SGLT2 inhibitors increase urinary excretion of glucose and lower plasma glucose levels in an insulin-independent manner. This article discusses the role of novel SGLT2 inhibitor canagliflozin in the treatment of T2DM.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded589    
    Comments [Add]    
    Cited by others 2    

Recommend this journal